143 patents
Page 2 of 8
Utility
PRODRUG INCORPORATED sgRNA SYNTHESIS
6 Apr 23
Disclosed herein include guide RNA (gRNA), such as single gRNA (sgRNA), and compositions thereof, comprising 2′-O-methyldithiomethyl modified sugar moieties which can be reduced to 2′-O-methanethiol groups in the reducing environment of cells and then converted (e.g., spontaneously converted) to 2′-OH.
Rajat Das, Ganapathy Sankaran
Filed: 23 Sep 22
Utility
Compositions and Methods for Differentiating Stem Cells into NK Cells
23 Mar 23
The disclosure features methods and compositions for differentiating stem cells into hematopoietic stem and progenitor cells (HSPC) and/or Natural Killer (NK) cells.
Viktoriia KYRYCHENKO, Wai Lun LEUNG, Patrick Claudio OVANDO ROCHE
Filed: 30 Aug 22
Utility
Universal Donor Cells
9 Mar 23
Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein.
Alireza REZANIA, Rebeca RAMOS-ZAYAS
Filed: 9 Aug 22
Utility
Universal Donor Cells
9 Mar 23
Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein.
Alireza REZANIA, Rebeca RAMOS-ZAYAS
Filed: 9 Aug 22
Utility
Characterizing Oligonucleotides
23 Feb 23
The present disclosure provides methods for determining oligonucleotide purity and/or characterizing small RNAs.
Luke J. Turechek
Filed: 19 Aug 22
Utility
Regulatable Expression Systems
16 Feb 23
Provided herein are regulatable expression systems and methods of using said regulatable expression systems to express proteins of interest.
Seshidhar Reddy Police, Kyungah Maeng
Filed: 1 Dec 20
Utility
Methods for Manufacturing Genetically Engineered Car-t Cells
16 Feb 23
Methods for manufacturing genetically engineered T cells expressing a chimeric antigen receptor (CAR), such as a CAR that binds human CD19, BCMA, or CD70, and having multiple additional gene edits, for example, a disrupted Regnase-1 gene, a disrupted TGFBRII gene, a disrupted TRAC gene, a disrupted β2M gene, or a combination thereof, using CRISPR/Cas gene editing systems.
Hui YU, Mary-Lee DEQUEANT, Demetrios KALAITZIDIS, Mohammed GHONIME
Filed: 26 Jul 22
Utility
Materials and Methods for Engineering Cells and Uses Thereof In Immuno-oncology
9 Feb 23
Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
Filed: 1 Oct 21
Utility
Materials and Methods for Engineering Cells and Uses Thereof In Immuno-oncology
26 Jan 23
Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
Filed: 1 Oct 21
Utility
Engineered Cells with Improved Protection from Natural Killer Cell Killing
19 Jan 23
Provided herein are cells engineered to have improved protection against natural killer cell killing.
Valentin SLUCH, Danielle SWAIN, Alireza REZANIA
Filed: 1 Jun 22
Utility
Engineered Cells with Improved Protection from Natural Killer Cell Killing
19 Jan 23
Provided herein are cells engineered to have improved protection against natural killer cell killing.
Valentin SLUCH, Danielle SWAIN, Alireza REZANIA
Filed: 1 Jun 22
Utility
Methods of Synthesizing Rna Molecules
29 Dec 22
The present disclosure relates to methods of synthesizing moderate length RNAs by splint-mediated ligation of RNA fragments.
Brian Joseph Cafferty, Jon Scott Munzer, Muthusamy Jayaraman, Rajat Subhra Das
Filed: 25 Nov 20
Utility
Therapy for Hematopoietic Cell Malignancies Using Genetically Engineered T Cells Targeting CD70
8 Dec 22
Aspects of the present disclosure relate to compositions comprising a population of genetically engineered T cells that expresses a chimeric antigen receptor (CAR) that binds CD70, and methods of using such for the treatment of T cell and B cell malignancies.
Jonathan Alexander TERRETT, Mary-Lee DEQUÉANT, Matthias WILL
Filed: 13 Nov 20
Utility
Genetically Engineered Immune Cells Targeting CD70 for Use In Treating Hematopoietic Malignancies
8 Dec 22
Aspects of the present disclosure relate to compositions comprising a population of genetically engineered T cells that expresses a chimeric antigen receptor (CAR) that binds CD70, and methods of using such for the treatment of T cell and B cell malignancies.
Jonathan Alexander TERRETT, Mary-Lee DEQUÉANT, Matthias WILL
Filed: 12 May 22
Utility
Renal Cell Carcinoma (RCC) Therapy Using Genetically Engineered T Cells Targeting CD70
8 Dec 22
Aspects of the present disclosure relate to compositions comprising a population of genetically engineered T cells that expresses a chimeric antigen receptor (CAR) that binds CD70, and methods of using such for the treatment of renal cell cancer (RCC).
Jonathan Alexander TERRETT, Mary-Lee DEQUÉANT, Matthias WILL
Filed: 13 Nov 20
Utility
Genetically Engineered Immune Cells Targeting CD70 for Use In Treating Solid Tumors
1 Dec 22
A method for treating a solid tumor (e.g., a CD70+ solid tumor) comprising one or more cycles of treatment, each cycle comprising administering to a human patient in need thereof an effective amount of a population of genetically engineered T cells after a lymphodepleting therapy, and optionally a treatment comprising an anti-CD38 antibody.
Jonathan Alexander TERRETT, Mary-Lee DEQUÉANT, Matthias WILL
Filed: 12 May 22
Utility
Mrna Large Scale Synthesis and Purification
17 Nov 22
Described herein is method for purifying messenger RNA (mRNA) encoding a DNA endonuclease from a sample, the method comprising: (a) loading the sample comprising the mRNA onto a monolithic matrix comprising a poly(dT) or poly(U) nucleic acid molecule linked/coupled to the monolithic matrix under conditions allowing the mRNA to hybridize with the poly(dT) or poly(U) nucleic acid molecule; (b) eluting the mRNA from the monolith matrix after one or more contaminants have been separated from the bound mRNA; and (c) separating the mRNA from dsRNA by adsorption chromatography, thereby resulting in a purified mRNA solution.
Christopher Cheng, Karolina Kosakowska, Caroline W. Reiss, Kui Wang
Filed: 11 May 22
Utility
Compositions and Methods for Editing the Angiopoietin-like 4 (ANGPTL4) Gene
17 Nov 22
The present application provides materials and methods for treating a patient with one or more conditions associated with ANGPTL4 whether ex vivo or in vivo.
Ante Sven Lundberg, Samarth Kulkarni, Lawrence Klein, Hari Kumar Padmanabhan
Filed: 21 Apr 22
Utility
Materials and Methods for Treatment of Apolipoprotein C3 (Apociii)-related Disorders
27 Oct 22
The present application provides materials and methods for treating a patient with one or more conditions associated with APOCIII whether ex vivo or in vivo.
Ante Sven Lundberg, Samarth Kulkarni, Lawrence Klein, Hari Kumar Padmanabhan
Filed: 2 May 22
Utility
Genetically Engineered T Cells with PTPN2 Knockout Have Improved Functionality and Anti-tumor Activity
15 Sep 22
A population of genetically engineered T cells, comprising a disrupted protein tyrosine phosphatase non-receptor type 2 (PTPN2) gene and optionally a disrupted TRAC gene, a disrupted β2M gene, and/or a disrupted CD70 gene.
Paul Tetteh
Filed: 8 Mar 22